Allergy Therapeutics (AGY) Receives “Buy” Rating from Numis Securities

Numis Securities reissued their buy rating on shares of Allergy Therapeutics (LON:AGY) in a research report sent to investors on Wednesday. They currently have a GBX 45 ($0.63) target price on the stock.

Separately, FinnCap restated a buy rating and issued a GBX 47 ($0.66) target price on shares of Allergy Therapeutics in a report on Tuesday, November 21st.

Shares of Allergy Therapeutics (LON:AGY) opened at GBX 28.30 ($0.40) on Wednesday. Allergy Therapeutics has a twelve month low of GBX 23 ($0.32) and a twelve month high of GBX 39.50 ($0.55).

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at

Allergy Therapeutics Company Profile

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.

Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply